LifeSemantics made a landmark cardio tech science achievement by receiving the MFDS approval to initiate a post-marketing surveillance (PMS) study. This pivotal study aims to assess the efficacy of its cutting-edge Artificial Intelligence (AI) software in evaluating risks associated with hypertension complications.
Revolutionizing cardiovascular risk assessment
The study will involve retrospective analysis of blood pressure data from 460 patients 18 years and older who were diagnosed with hypertension and have attended Chonnam National University Hospital within the past year. Through meticulous examination of detailed blood pressure information, LifeSemantics aims to determine the likelihood of patients developing cardiac and cerebrovascular events related to arteriosclerotic cardiovascular disease (ASCVD). This project not only creates the opportunity for AI to change healthcare outcomes but also proves to the investigational medical device that software is the best and most effective one, regardless of the issue, to succeed.
Innovative approaches to hypertension management
At the core of the LifeSemantics project mentioned is the plan to commercialize a medical AI app named “Cardiovascular Risk Assessment AI.” This goes along with other products that are already under development or have been released by the company later; for instance, the recently finished license application of Lifesemantics for a blood pressure prediction AI known as “Canofy MD BPAI.” The integration of these technologies promises a future where hypertensive patients can benefit from a robust health management system, potentially preventing the onset of atherosclerotic cardiovascular disease.
The actual influence of the cardiovascular risk assessment AI is considerable, bringing prevention in pursuit of hypertension complications and management of these complications. Given the high economic burden of treating hypertension-related issues and the critical need for early intervention, this technology stands to significantly aid patients in managing their health more effectively.
Heo Eun-young, head of the Technology Commercialization Research Center at LifeSemantics, expressed the company’s dedication to enhancing the competitiveness of its medical AI software. Through the delivery of product innovations and joint marketing with the Canofy MD BPAI, LifeSemantics has set the stage to virtually stand a lot and support the medical industry.”We will do our best to enhance the competitiveness of our medical AI software through product advancements, including the combined commercialization with Canofy MD BPAI, and help the medical field,” stated Heo.
The innovation reflects the principle of LifeSemantics, which is nothing else but an innovative approach to pursuing the workplace as a rule of advancing not only health technology but also offering practical solutions for early detection and management of hypertension and its complications.
The future of AI in healthcare
AI systems have faced numerous challenges in the healthcare industry, but lifeSemantics clinical trial truly is a giant leap in the AI applied to medical care. By leveraging advanced technology to assess cardiovascular risk, the company is at the forefront of creating more efficient, accurate, and personalized healthcare solutions. As the trial unfolds, AI may be used to support the health care of patients and prevent diseases in a way that can stand out from other medical technologies. Hence, this trial is a milestone.
LifeSemantics’ approval to conduct a clinical trial on its cardiovascular risk assessment AI software is a testament to the potential of AI in revolutionizing healthcare practices. By setting the goal to prevent atherosclerosis of the cardiovascular system in patients with hypertension, the company is forerunning the industry, making it possible to coordinate healthcare activities more efficiently. As LifeSemantics continues to advance its technologies, the medical community eagerly anticipates the outcomes of this research and its implications for the future of healthcare innovation.
Original Story From koreabiomed
